Auto-Brewery Syndrome: What the Medical Literature Reports

Auto-brewery syndrome (ABS) sits at an unusual position in the medical literature: it is a condition with a plausible and well-characterised physiological mechanism, documented in case reports spanning seven decades, yet without a single randomised controlled trial, no formally standardised diagnostic criteria, and — until relatively recently — limited awareness even among specialist clinicians.

This overview summarises what the published case literature and emerging research report about the condition: its causative organisms, investigation approaches, management outcomes, and the significant evidence gaps that remain.

History and Case Literature

Cases of apparent endogenous ethanol production were first described in Japanese literature in the 1950s, predominantly in patients with conditions affecting gastrointestinal anatomy or motility. A systematic case series published by Kaji and colleagues in 1984 documented multiple patients with measurable blood alcohol levels following carbohydrate ingestion and identified S. cerevisiae as the causative organism in several cases.

A widely referenced US case report by Cordell and McCarthy (2013) described a patient who experienced ABS episodes for several years, was initially disbelieved by clinicians and law enforcement, and eventually received formal diagnosis through controlled provocation testing. This case brought significant attention to the condition in English-language medical and lay literature. Cordell subsequently published further case series and contributed substantially to awareness of ABS as a clinically real and diagnosable entity.

Causative Organisms

Across published cases, fungal species are the most commonly identified causative organisms. Saccharomyces cerevisiae (brewer's yeast) appears most frequently, followed by Candida albicans and Candida glabrata. Torulaspora delbrueckii and other yeast species have been reported in isolated cases.

Bacterial-aetiology ABS has also been documented. Klebsiella pneumoniae, which can ferment sugars to produce ethanol under certain conditions, has been identified in several cases, particularly in Asian populations where it has been associated with non-alcoholic fatty liver disease. This suggests that bacterial ABS may represent a distinct subtype with a different distribution.

Predisposing Factors in Reported Cases

A consistent theme across reported cases is a history of prior antibiotic use — often prolonged or repeated — which is understood to disrupt the gut microbiome's normal bacterial populations, reducing competitive inhibition of fungal overgrowth. High-carbohydrate and high-sugar dietary patterns provide the fermentation substrate. Structural gastrointestinal conditions (short bowel syndrome, blind loop syndrome, Crohn's disease) feature in a subset of cases, presumably by altering transit time and creating fermentation-favourable conditions. Diabetes and immune suppression have also been noted in some reported cases.

Investigation in Published Cases

The controlled provocation test — carbohydrate ingestion under monitored fasting conditions with serial blood alcohol measurement — is the primary diagnostic approach described across published cases. There is no universally agreed protocol for carbohydrate load, fasting duration, or frequency of blood sampling, reflecting the absence of formal guideline development in this area.

Stool culture, small intestinal aspirate culture, and in some cases intestinal biopsy have been used to identify causative organisms. Breath ethanol testing has been used as a less invasive monitoring tool in some protocols. Gut microbiome sequencing, whilst not a standardised diagnostic tool, has been used in more recent cases to characterise the microbiome composition more comprehensively.

Reported Management Outcomes

The most consistent management finding across published cases is the effectiveness of dietary carbohydrate restriction. In the majority of documented cases, significant reduction in dietary carbohydrate and sugar resulted in substantial symptomatic improvement. This is mechanistically consistent: reducing fermentation substrate limits ethanol production regardless of the organism involved.

Antifungal pharmacotherapy — most commonly fluconazole, sometimes combined with nystatin — has been associated with symptom resolution in fungal-aetiology cases, particularly when combined with dietary change. Bacterial-aetiology cases have been treated with targeted antibiotics. Probiotic supplementation has been included in some published treatment protocols, though evidence for specific strains or formulations in ABS is not yet available.

Relapse is documented in a meaningful proportion of cases. Published case series have reported return of symptoms following resumption of high-carbohydrate dietary patterns, even after successful pharmacological treatment. This suggests that dietary management may need to be sustained indefinitely in many cases, rather than treating it as a temporary adjunct to antifungal therapy.

Evidence Gaps and Research Needs

The most significant limitation of the current ABS evidence base is its reliance on case reports. This means that prevalence, incidence, demographic distribution, and comparative treatment effectiveness cannot be reliably estimated. No randomised controlled trials of any intervention for ABS exist. Formal diagnostic criteria have not been agreed upon, and investigation protocols are not standardised across health systems.

Increased clinician awareness — which has grown substantially since the condition gained broader attention in the 2010s — is a prerequisite for better case identification and, eventually, prospective research. Patient and advocacy organisations have begun contributing to awareness and to the collection of patient-reported data, which may provide a foundation for more systematic study. The condition almost certainly remains significantly under-diagnosed, which itself represents a research and clinical priority.